138 related articles for article (PubMed ID: 10534147)
1. Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1-infected individuals.
Weber R; Christen L; Loy M; Schaller S; Christen S; Joyce CR; Ledermann U; Ledergerber B; Cone R; Lüthy R; Cohen MR
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):56-64. PubMed ID: 10534147
[TBL] [Abstract][Full Text] [Related]
2. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms.
Burack JH; Cohen MR; Hahn JA; Abrams DI
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):386-93. PubMed ID: 8673548
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
4. Herbal medicines for treating HIV infection and AIDS.
Liu JP; Manheimer E; Yang M
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD003937. PubMed ID: 16034917
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.
Angel JB; Jacobson MA; Skolnik PR; Giordano M; Shapiro L; LeBeaut A; Greaves W; Fuchs AC
AIDS; 2000 Nov; 14(16):2503-8. PubMed ID: 11101061
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
9. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
[TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI; Goodall RL; Dunn DT; Franzen S; Collaco-Moraes Y; Gazzard BG; Williams IG; Fisher MJ; Winston A; Fox J; Orkin C; Herieka EA; Ainsworth JG; Post FA; Wansbrough-Jones M; Kelleher P;
JAMA; 2012 Jul; 308(4):353-61. PubMed ID: 22820788
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Mianyi granules (+mianyi+) for reversal of immune nonresponse following antiretroviral therapy of human immunodeficiency virus-1: a randomized, double-blind, multi-center, placebo-controlled trial.
Ying L; Wen Z; Qingfei X; Xin D; Fuchun Z; Li W; Yonghong LI; Wenhui L; Jian W
J Tradit Chin Med; 2022 Jun; 42(3):432-438. PubMed ID: 35610013
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.
Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S
JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590
[TBL] [Abstract][Full Text] [Related]
18. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
19. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
20. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
